ANTIMONIAL TREATMENT FAILURE RATE IN PATIENTS WITH CUTANEOUS LEISHMANIASIS

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

JAFFARY FARIBA; NILFOROUSHZADEH MOHAMMAD ALI; ABDELLAHI LATIFEH; TAHMASEBI POOR HADIS

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: TEHRAN UNIVERSITY MEDICAL JOURNAL (TUMJ) Year:2018 | Volume:76 | Issue:3 Page(s): 197-203

Download Full-Text

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Verion

View:

775

Download:

Cites:

Information Journal Paper

Title

ANTIMONIAL TREATMENT FAILURE RATE IN PATIENTS WITH CUTANEOUS LEISHMANIASIS

Author(s)

JAFFARY FARIBA | NILFOROUSHZADEH MOHAMMAD ALI | ABDELLAHI LATIFEH | TAHMASEBI POOR HADIS | Issue Writer Certificate

Keywords

CUTANEOUS LEISHMANIASISQ2

MEGLUMINE ANTIMONIATEQ2

TREATMENT FAILUREQ1

Abstract

Background: Despite advances in diagnosis and treatment, leishmaniasis is now considereda severe public health problem, particularly in developing countries, such asIran. Leishmaniasis is among the six most important, parasitic diseases of the worldaffecting 88 countries in almost every continent. The disease is complex with differentclinical presentations such as visceral, cutaneous and mucocutaneous forms. Cutaneousleishmaniasis (CL) is the most common form of the disease in Iran. Antimony compoundsare the first line treatment of CL. The treatment of leishmaniasis in endemicareas relies on chemotherapy, and in several parts of the world the mainstay remains thepentavalent antimony (SbV)-containing drugs Pentostam (sodium stibogluconate) andGlucantime (meglumine). There is no comprehensive study on TREATMENT FAILURE rate ofthis compounds. This study was designed to evaluate TREATMENT FAILURE rate and possibleinvolving factors of antimonial resistance in CL to facilitate and improve treatmentstrategies of this disease. Methods: All patients with CL referred to Skin Disease and Leishmaniasis Research Center(SDLRC), from October 2011 to October 2013, treated with antimony compoundswere assessed in this study. Patient characteristics (gender, age and place of residence), number, type and location of the lesions, comorbidities and type of treatment were recordedand analyzed. Results: Rate of TREATMENT FAILURE with Meglusan was 4. 3%. Failure rate in men and inpatients with previous history of CUTANEOUS LEISHMANIASIS was more than women or patientswithout CL history (P= 0. 000, 0. 024 respectively). The results of this studyshowed that TREATMENT FAILURE was higher in patients with systemic treatment than intralesional(IL) or combination therapy (both IL and systemic treatment) group but thisdifference was not statistically significant. Also, size and number of the lesions, woundinfection, the patient's age, location, education and occupation do not have a significantcorrelation with TREATMENT FAILURE. Conclusion: Greater TREATMENT FAILURE rate of Meglusan compared to Glucantime (4. 3%versus< 1%, respectively) is an important issue to be considered in CL therapeutic strategy.

Cites

Factors affecting the antimonial treatment duration rate in patients with cutaneous leishmaniasis: survival analysis model

References

No record.

Cite

APA: Copy

JAFFARY, FARIBA, NILFOROUSHZADEH, MOHAMMAD ALI, ABDELLAHI, LATIFEH, & TAHMASEBI POOR, HADIS. (2018). ANTIMONIAL TREATMENT FAILURE RATE IN PATIENTS WITH CUTANEOUS LEISHMANIASIS. TEHRAN UNIVERSITY MEDICAL JOURNAL (TUMJ), 76(3 ), 197-203. SID. https://sid.ir/paper/38534/en

Vancouver: Copy

JAFFARY FARIBA, NILFOROUSHZADEH MOHAMMAD ALI, ABDELLAHI LATIFEH, TAHMASEBI POOR HADIS. ANTIMONIAL TREATMENT FAILURE RATE IN PATIENTS WITH CUTANEOUS LEISHMANIASIS. TEHRAN UNIVERSITY MEDICAL JOURNAL (TUMJ)[Internet]. 2018;76(3 ):197-203. Available from: https://sid.ir/paper/38534/en

IEEE: Copy

FARIBA JAFFARY, MOHAMMAD ALI NILFOROUSHZADEH, LATIFEH ABDELLAHI, and HADIS TAHMASEBI POOR, “ANTIMONIAL TREATMENT FAILURE RATE IN PATIENTS WITH CUTANEOUS LEISHMANIASIS,” TEHRAN UNIVERSITY MEDICAL JOURNAL (TUMJ), vol. 76, no. 3 , pp. 197–203, 2018, [Online]. Available: https://sid.ir/paper/38534/en

Related Journal Papers